A Look Into The Future Of NASH

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.

Liver disease
A plethora of drug candidates are in development for NASH

Sometimes advances in drug development are like London buses: you wait for ages, and then loads turn up at once. This has certainly been the case in the non-alcoholic steatohepatitis (NASH) space recently, with several mid-stage trials yielding positive – or positive-ish – data in the past few months.

Key Takeaways

  • Madrigal’s resmetirom is likely to become the first drug approved in NASH later this year

But there is much more to come. Players including Novo Nordisk A/S, Boehringer Ingelheim GmbH, Pfizer Inc....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.